Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
Senate launches investigation into high prices of Ozempic and Wegovy in the U.S.
03:22pm, Wednesday, 24'th Apr 2024
Before insurance, Novo Nordisk charges about $1,000 per month for Ozempic in the United States. In Germany, the company charges $59 a month for the same drug.
US Senate committee investigates pricing of Novo's Ozempic and Wegovy
02:37pm, Wednesday, 24'th Apr 2024
A U.S. Senate committee said on Wednesday it had launched an investigation into the prices of Novo Nordisk's diabetes and weight loss drugs Ozempic and Wegovy in the United States.
3 Biotech Stocks With Skyrocketing Potential: April 2024
11:36am, Wednesday, 24'th Apr 2024
Investing in biotech stocks is not for the faint of heart. The sector is prone to wild swings in stock prices, offering a distinctive blend of high risk and high reward.
4 Large Drug Stocks to Hold on to Amid Industry Challenges
11:11am, Wednesday, 24'th Apr 2024
Drug and biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and AbbVie (ABBV) are worth retaining i
Missed Out on Novo Nordisk? 2 Healthcare Stocks With Big Catalysts on the Horizon.
05:50am, Wednesday, 24'th Apr 2024
Novo Nordisk has achieved tremendous success thanks largely to Ozempic and Wegovy. Vertex Pharmaceuticals is another drugmaker that could soon have two new big winners on the market.
Novo Nordisk (NVO) Boasts Earnings & Price Momentum: Should You Buy?
10:31am, Tuesday, 23'rd Apr 2024
Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service.
Why Novo Nordisk Topped the Market Today
06:08pm, Monday, 22'nd Apr 2024
The Wegovy and Ozempic maker continues to buy its own shares. It purchased more than 200,000 of them last week.
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
06:05am, Monday, 22'nd Apr 2024
The GLP-1 weight loss trend continues to flourish, and the ante keeps rising. The reigning champions in the battle of the bulge are Novo Nordisk A/V NYSE: NVO with its Semaglutide medications Ozempic
2 Everlasting Big Pharma Stocks to Buy Today and Hold Forever
09:45am, Saturday, 20'th Apr 2024
Great pharma companies tend to be entrenched in lucrative markets. Vertex Pharmaceuticals is managing to diversify off a strong base.
Missed Out on Eli Lilly and Novo Nordisk? This Small Biotech Has a Promising GLP-1 Drug With Significant Potential
08:30am, Saturday, 20'th Apr 2024
Eli Lilly and Novo Nordisk are two of the big names in healthcare focused on a hot GLP-1 drug market. But there's a drug from a smaller biotech which could also prove to be a big player in this area.
3 Relatively Safe Growth Stocks You Can Buy and Hold
06:48am, Saturday, 20'th Apr 2024
Eli Lilly has crushed the S&P 500 over the last 12 months and could continue delivering outsized returns. Novo Nordisk's strong fundamentals and solid growth opportunities make it a no-brainer buy.
3 Biotech Stocks Set to Double by 2028
06:15am, Saturday, 20'th Apr 2024
Biotech stocks offer the possibility of groundbreaking medical advancements alongside the potential for explosive growth. While the sector carries inherent risks, a select group of biotech companies p
Got $500? 3 Healthcare Stocks to Buy and Hold Forever
08:15am, Friday, 19'th Apr 2024
Healthcare stocks can be excellent choices for investors, offering a balance of safety and growth. Intuitive Surgical, Bristol Myers Squibb, and Novo Nordisk all have strong growth potential.
NVO, ELF, TAN: Stocks & ETFs to Watch
05:31pm, Wednesday, 17'th Apr 2024
Mish Schneider discusses her stock and ETF picks as stocks continue to tick lower today. She highlights Novo Nordisk (NVO), E.L.F. Beauty (ELF), and Invesco Solar ETF (TAN). Tune in to find out more a
Big pharma is looking to fatten profits with buyouts of weight-loss drug companies. Here are 4 candidates.
07:09pm, Tuesday, 16'th Apr 2024
A couple of big-picture trends in biotech could add up to a nice investment opportunity. First, corporate buyouts are back in style.
